Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

9480	Companies
185531	Keywords
117925	Articles
99377	Press releases

Home
Companies
Biophytis

BRIEF

published on 07/11/2024 at 07:06, 1 year 4 months ago

Biophytis Receives FDA IND Approval for Phase 2 Obesity Study

Biophytis FDA Approval Phase 2 Study BIO101 Obesity
REGULATED PRESS RELEASE

published on 07/11/2024 at 07:01, 1 year 4 months ago

Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity
Biophytis obtains FDA approval to start phase 2 OBA study in obesity with BIO101 (20-hydroxyecdysone), focusing on muscle strength improvement. Study led by Prof. Marc-André Cornier to start mid-2024 in the USA

Biophytis FDA Approval Obesity Treatment BIO101 Phase 2 OBA Study
BRIEF

published on 07/01/2024 at 07:05, 1 year 5 months ago

Biophytis Presents Promising Phase 2-3 COVA Study Results on Severe Covid-19 at WCID in Paris

Biophytis COVID-19 Clinical Trials COVA Study Infectious Diseases
PRESS RELEASE

published on 07/01/2024 at 07:00, 1 year 5 months ago

Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris
Biophytis presents positive results from Phase 2-3 COVA study for severe Covid-19 at WCID Paris. Bio101 shows significant efficacy and safety in reducing risk of respiratory failure and death

Biophytis COVID-19 Positive Results Phase 2-3 COVA Study Respiratory Failure
REGULATED PRESS RELEASE

published on 07/01/2024 at 07:00, 1 year 5 months ago

Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris
Biophytis presented positive results of its Phase 2-3 COVA study for severe Covid-19 at WCID in Paris, showing reduction in respiratory failure and death rates

Biophytis COVID-19 Positive Results Phase 2-3 COVA Study
BRIEF

published on 06/25/2024 at 23:05, 1 year 5 months ago

Biophytis Approves All Resolutions at General Meeting

Shareholders Biophytis General Meeting Resolutions
REGULATED PRESS RELEASE

published on 06/25/2024 at 23:00, 1 year 5 months ago

RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024
Biophytis SA announces the approval of all resolutions at the combined general meeting held on June 24, 2024, with significant shareholder participation

Shareholders General Meeting Resolutions Approval Biophytis SA
BRIEF

published on 06/20/2024 at 07:05, 1 year 5 months ago

Biophytis Grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at Up to €108 Million

Biophytis Pharmaceuticals Latin America BIO101 Blanver
PRESS RELEASE

published on 06/20/2024 at 07:00, 1 year 5 months ago

Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million
Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 million. Agreement includes upfront and milestones payments, double-digit royalties, and collaboration on manufacturing and clinical development

Biophytis Latin America Exclusive Rights Blanver Pharmaceutical Deal
REGULATED PRESS RELEASE

published on 06/20/2024 at 07:00, 1 year 5 months ago

Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million
Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million. Collaboration for commercialization and clinical development announced

Biophytis Latin America BIO101 Exclusive Rights Blanver

Accesswire

Published on 12/05/2025 at 19:20, 14 minutes ago

The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 49 minutes ago

Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove
Published on 12/05/2025 at 18:20, 1 hour 14 minutes ago

NuRAN Announces Intention to Complete Consolidation in Preparation to the Restructuring Transaction
Published on 12/05/2025 at 18:00, 1 hour 34 minutes ago

SMX: A New Supply Chain Reality in the World's Four Largest Markets
Published on 12/05/2025 at 17:15, 2 hours 19 minutes ago

TRX GOLD Attending the 3rd Annual DealFlow Discovery Conference

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:58, 35 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 1 hour 7 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 1 hour 18 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 1 hour 42 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 1 hour 47 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds

Les Echos

Published on 12/05/2025 at 17:18, 2 hours 16 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 4 hours 23 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 08:45, 10 hours 49 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 1 day 1 hour ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 1 day 1 hour ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE